Updates are available Correction dated 2024-07-22
Click to view Correction: https://doi.org/10.1007/s10616-024-00644-z
-
Authors
Maeda, Satoshi
Matsumoto, Masaya
Segawa, Kotaro
Iwamoto, Kaori
Nakamura, Norimasa
-
Funding
Funding for this research was provided by:
TWOCELLS Co., Ltd
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 18 June 2024
First Online: 2 July 2024
Change Date: 22 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10616-024-00644-z
Declarations
:
: S.M., K.S. and K.I. are employees, M.M. is a board member of TWOCELLS Co. Ltd., and N.N. has received a research grant from TWOCELLS Co. Ltd.
: The study was approved by the both Ethics Committees of Osaka University and TWOCELLS Co. Ltd., titled “Clinical trial and commercial use of gMSC produced from allogenic synovial mesenchymal stem cells,” with approval no. 15509 (July 13, 2016) and 22 (August 24, 2016), respectively, and “Tissue regeneration using cultured skeletal muscle, synovium, and adipose-derived stem cells,” with approval no. 14102 (February 05, 2015) and 28 (April 19, 2018), respectively followed the Declaration of Helsinki. After obtaining informed consent, the synovium was obtained from the surgical waste of healthy patients undergoing knee surgery.
: Not applicable.
